Eph receptors and ephrins as targets for cancer therapy
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Eph receptor tyrosine kinases and their ephrin ligands are involved in various signalling pathways and mediate critical steps of a wide variety of physiological and pathological processes. Increasing experimental evidence demonstrates that both Eph receptor and ephrin ligands are overexpressed in a number of human tumours, and are associated with tumour growth, invasiveness and metastasis. In this regard, the Eph/ephrin system provides the foundation for potentially exciting new targets for anticancer therapies for Eph‐expressing tumours. The purpose of this review is to outline current advances in the role of Eph receptors and ephrin ligands in cancer, and to discuss novel therapeutic approaches of anticancer therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Penzes, P., Beeser, A., Chernoff, J., Schiller, M. R., Eipper, B. A., Mains, R. E., & Huganir, R. L. (2003) · Neuron · doi:10.1016/s0896-6273(02)01168-6 · Cited by 466 · cited 2×
“EphB receptors appear to associate with the exchange factors intersectin [54] and kalirin [55].”
BackgroundLamberto, I., Qin, H., Noberini, R., Premkumar, L., Bourgin, C., Riedl, S. J., Song, J., & Pasquale, E. B. (2012) · Biochemical Journal · doi:10.1042/bj20120408 · Cited by 48 · cited 1×
“[160] have reported that KYL, APY and VTM antagonistic peptides could selectively target EphA4 to inhibit ephrin binding to EphA4.”
Background
Research works printed but not linked: 206
- 10.1038/35058515 · DOI · Paper page
- 10.1016/S1357-2725(02)00096-1 · DOI · Paper page
- 10.1002/jcb.21926 · DOI
- 10.1016/S0092-8674(00)80500-0 · DOI · Paper page
- 10.1126/science.2825356 · DOI · Paper page
- 10.1038/368558a0 · DOI · Paper page
- 10.1002/j.1460-2075.1994.tb06685.x · DOI
- 10.1101/gad.1093703 · DOI · Paper page
- 10.1038/modpathol.3800660 · DOI
- 10.1002/(SICI)1097-0215(19991022)84:5<494::AID-IJC8>3.0.CO;2-O · DOI
- Vogt T, 1998, Overexpression of Lerk‐5/Eplg5 messenger RNA: a novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas, Clin Cancer Res, 4, 791
- 10.1073/pnas.190123297 · doi:10.1073/pnas.190123297
- 10.1158/1535-7163.MCT-07-0200 · DOI
- 10.1593/neo.05277 · doi:10.1593/neo.05277
- 10.1038/sj.bjc.6604676 · DOI · Paper page
- Zelinski DP, 2001, EphA2 overexpression causes tumorigenesis of mammary epithelial cells, Cancer Res, 61, 2301
- 10.1016/j.bbrc.2004.04.102 · DOI · Paper page
- Berclaz G, 2002, Loss of EphB4 receptor tyrosine kinase protein expression during carcinogenesis of the human breast, Oncol Rep, 9, 985
- 10.1373/clinchem.2003.026849 · DOI · Paper page
- 10.1038/nature03626 · DOI · Paper page
- 10.1002/ijc.23890 · doi:10.1002/ijc.23890
- 10.1002/(SICI)1097-0045(19991201)41:4<275::AID-PROS8>3.0.CO;2-T · DOI · Paper page
- Kinch MS, 2003, Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival, Clin Cancer Res, 9, 613
- 10.1111/j.1349-7006.2005.00007.x · doi:10.1111/j.1349-7006.2005.00007.x
- 10.1007/s00432-002-0355-0 · doi:10.1007/s00432-002-0355-0
- 10.1517/14728222.9.6.1179 · DOI · Paper page
- 10.1186/1471-2407-6-144 · DOI
- 10.1002/ijc.10860 · DOI · Paper page
- 10.4149/neo_2009_04_331 · doi:10.4149/neo_2009_04_331
- 10.1136/gut.2004.049486 · DOI
- 10.12659/MSM.881929 · doi:10.12659/msm.881929
- Kiyokawa E, 1994, Overexpression of ERK, an EPH family receptor protein tyrosine kinase, in various human tumors, Cancer Res, 54, 3645
- 10.1016/S0896-6273(00)80706-0 · DOI · Paper page
- 10.1016/S0896-6273(00)80663-7 · DOI · Paper page
- 10.1038/nrm856 · DOI · Paper page
- 10.1038/nn1237 · DOI · Paper page
- 10.1016/S0896-6273(00)80276-7 · DOI · Paper page
- 10.1021/bi991628t · DOI
- 10.1016/j.tcb.2007.03.004 · DOI · Paper page
- 10.1016/j.neures.2003.11.009 · doi:10.1016/j.neures.2003.11.009
- 10.1038/nn1655 · DOI · Paper page
- 10.1016/S0166-2236(02)00005-X · DOI · Paper page
- 10.1126/stke.2001.112.re20 · doi:10.1126/stke.2001.112.re20
- 10.1074/jbc.M500010200 · DOI
- 10.1038/sj.onc.1208584 · doi:10.1038/sj.onc.1208584
- 10.1128/MCB.21.14.4579-4597.2001 · doi:10.1128/mcb.21.14.4579-4597.2001
- 10.1042/BJ20090014 · DOI
- 10.1038/nrm1662 · DOI · Paper page
- 10.1038/35000008 · DOI · Paper page
- 10.1074/jbc.M313356200 · DOI
- 10.1016/0092-8674(95)90370-4 · DOI · Paper page
- 10.1016/S0092-8674(01)00314-2 · DOI · Paper page
- Lawrenson ID, 2002, Ephrin‐A5 induces rounding, blebbing and de‐adhesion of EphA3‐expressing 293T and melanoma cells by CrkII and Rho‐mediated signalling, J Cell Sci, 115, 1059, 10.1242/jcs.115.5.1059 · DOI · Paper page
- 10.1038/nn964 · DOI · Paper page
- 10.1073/pnas.96.24.13813 · DOI · Paper page
- 10.1038/35074604 · DOI · Paper page
- 10.1038/35065000 · DOI · Paper page
- 10.1126/science.1072682 · DOI · Paper page
- 10.1128/MCB.21.21.7429-7441.2001 · DOI · Paper page
- 10.1038/sj.onc.1205758 · DOI
- 10.1038/sj.onc.1203304 · DOI
- 10.1074/jbc.M208972200 · DOI
- 10.1016/j.cell.2009.08.048 · DOI · Paper page
- 10.1016/j.cell.2006.04.030 · DOI · Paper page
- 10.1038/ncb1438 · DOI · Paper page
- 10.1126/science.275.5306.1640 · DOI · Paper page
- 10.1101/gad.13.23.3125 · DOI · Paper page
- 10.1016/j.cell.2012.01.024 · DOI · Paper page
- 10.1091/mbc.12.3.685 · DOI · Paper page
- 10.1126/science.1719635 · DOI · Paper page
- 10.1074/jbc.273.39.25279 · DOI
- 10.1074/jbc.M008127200 · DOI · Paper page
- 10.1093/emboj/19.20.5396 · DOI · Paper page
- 10.1038/383722a0 · DOI · Paper page
- 10.1101/gad.1630408 · DOI · Paper page
- 10.1038/35093123 · DOI · Paper page
- 10.1016/S0092-8674(01)00297-5 · DOI · Paper page
- 10.1038/20452 · DOI · Paper page
- 10.1016/S0092-8674(01)00191-X · DOI · Paper page
- 10.1242/jcs.115.15.3073 · DOI · Paper page
- 10.1016/0092-8674(95)90421-2 · DOI · Paper page
- 10.1016/0896-6273(95)90335-6 · DOI · Paper page
- 10.1016/S0896-6273(00)81240-4 · DOI · Paper page
- 10.1016/S0092-8674(00)00197-5 · DOI · Paper page
- 10.1016/S0896-6273(01)00440-8 · DOI · Paper page
- 10.1016/S0092-8674(02)01015-2 · DOI · Paper page
- 10.1093/emboj/18.19.5159 · DOI
- 10.1002/ijc.25147 · DOI · Paper page
- 10.1006/scdb.2001.0289 · DOI
- 10.1242/jcs.02777 · DOI
- 10.1038/35058582 · DOI
- 10.2174/1381612043383160 · DOI
- 10.1016/S0002-9440(10)63899-0 · DOI
- 10.1096/fj.05-4038fje · DOI
- 10.1038/sj.onc.1208937 · DOI
- 10.1172/JCI33154 · DOI · Paper page
- 10.1158/1541-7786.MCR-06-0321 · DOI
- 10.1074/jbc.M111.329466 · DOI
- 10.2353/ajpath.2006.050889 · DOI · Paper page
- 10.1371/journal.pone.0024426 · DOI
- 10.1038/sj.bjc.6604970 · DOI
- 10.1016/S0304-3835(01)00613-9 · DOI
- 10.1136/jcp.2010.087213 · DOI
- 10.1093/carcin/bgi259 · DOI · Paper page
- 10.1158/1078-0432.CCR-05-0143 · DOI
- Oshima T, 2008, Overexpression of EphA4 gene and reduced expression of EphB2 gene correlates with liver metastasis in colorectal cancer, Int J Oncol, 33, 573
- 10.1093/carcin/bgp133 · DOI
- 10.1002/cncr.10122 · DOI · Paper page
- 10.1186/1471-2199-2-15 · doi:10.1186/1471-2199-2-15
- 10.1038/ncb2122 · DOI · Paper page
- 10.1146/annurev.neuro.21.1.309 · DOI · Paper page
- 10.1242/dev.126.10.2033 · DOI · Paper page
- 10.1016/j.brainresrev.2005.02.001 · DOI
- 10.1158/1541-7786.MCR-05-0056 · DOI · Paper page
- 10.1158/1535-7163.MCT-07-2263 · DOI
- 10.1186/1471-2407-8-79 · DOI
- 10.1038/nature03651 · DOI · Paper page
- 10.1158/0008-5472.CAN-03-3667 · DOI · Paper page
- 10.1158/0008-5472.CAN-05-4211 · DOI
- 10.1023/A:1022546620495 · DOI
- 10.1038/sj.onc.1206447 · DOI · Paper page
- 10.4161/cbt.5.2.2510 · doi:10.4161/cbt.5.2.2510
- 10.1038/onc.2011.210 · DOI · Paper page
- 10.1002/ijc.2910600119 · doi:10.1002/ijc.2910600119
- 10.1074/jbc.M109.075085 · DOI
- 10.1158/0008-5472.CAN-10-0717 · DOI
- 10.1038/ncomms1675 · DOI
- 10.1002/hep.20878 · DOI · Paper page
- Wang J, 2010, Expression of EphA1 in gastric carcinomas is associated with metastasis and survival, Oncol Rep, 24, 1577
- 10.1007/s12253-008-9132-y · DOI
- 10.4149/neo_2012_014 · doi:10.4149/neo_2012_014
- 10.1007/s00535-012-0549-4 · DOI
- 10.1038/sj.onc.1209780 · DOI
- 10.1007/s00432-010-0861-4 · DOI
- 10.2353/ajpath.2007.070033 · doi:10.2353/ajpath.2007.070033
- 10.1016/S0092-8674(00)80108-7 · DOI · Paper page
- 10.1055/s-0038-1657610 · DOI · Paper page
- 10.1093/jnci/82.1.4 · DOI · Paper page
- 10.1038/nrc2806 · DOI · Paper page
- 10.1038/sj.onc.1204004 · DOI · Paper page
- 10.1038/sj.onc.1205679 · DOI · Paper page
- 10.1016/j.biocel.2008.07.019 · DOI
- 10.1152/ajplung.90256.2008 · DOI · Paper page
- 10.1016/j.oraloncology.2008.01.018 · DOI
- 10.1073/pnas.0401381101 · DOI · Paper page
- 10.1007/s10456-010-9183-z · DOI
- 10.1038/nature08995 · DOI · Paper page
- 10.1016/S1476-5586(03)80047-7 · DOI
- 10.1158/0008-5472.CAN-3430-2 · DOI · Paper page
- 10.2174/1568009053765780 · DOI · Paper page
- 10.1158/1541-7786.MCR-08-0244 · DOI · Paper page
- 10.1016/j.tcm.2007.03.003 · DOI · Paper page
- 10.1182/blood-2008-02-140020 · doi:10.1182/blood-2008-02-140020
- 10.1182/blood-2005-04-1655 · DOI · Paper page
- 10.1593/neo.03457 · DOI
- 10.1158/0008-5472.CAN-03-1047 · DOI · Paper page
- 10.1074/jbc.M500363200 · DOI · Paper page
- 10.1016/j.mcn.2003.08.006 · DOI
- 10.1074/jbc.M804103200 · DOI · Paper page
- Coffman KT, 2003, Differential EphA2 epitope display on normal versus malignant cells, Cancer Res, 63, 7907
- 10.1093/jnci/djj414 · DOI
- 10.4049/jimmunol.181.11.7721 · DOI
- 10.1016/j.bmcl.2006.09.050 · doi:10.1016/j.bmcl.2006.09.050
- 10.1016/j.bmcl.2008.09.087 · doi:10.1016/j.bmcl.2008.09.087
- 10.1016/j.bmcl.2009.05.029 · DOI
- 10.1021/jm9009444 · DOI
- 10.1016/j.bmcl.2009.09.010 · DOI
- 10.2165/00063030-200822010-00007 · DOI
- 10.1158/1541-7786.MCR-08-0169 · DOI · Paper page
- 10.1038/sj.bjc.6605101 · DOI · Paper page
- 10.1038/sj.bjc.6605381 · DOI
- 10.1038/sj.onc.1207247 · DOI · Paper page
- 10.1186/1476-4598-1-2 · DOI
- 10.1016/j.surneu.2008.04.031 · DOI
- 10.1158/0008-5472.CAN-05-0530 · DOI · Paper page
- 10.4161/cbt.8.11.8523 · DOI
- 10.1158/0008-5472.CAN-08-1933 · DOI · Paper page
- 10.1093/jnci/djp231 · DOI
- 10.1038/nbt832 · DOI · Paper page
- 10.1007/s00259-007-0503-5 · DOI
- 10.1158/0008-5472.CAN-05-0758 · DOI
- 10.1158/0008-5472.CAN-06-2760 · DOI · Paper page
- Tatsumi T, 2003, Disease stage variation in CD4+ and CD8+ T‐cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma, Cancer Res, 63, 4481
- Alves PM, 2003, EphA2 as target of anticancer immunotherapy: identification of HLA‐A*0201‐restricted epitopes, Cancer Res, 63, 8476
- 10.1002/cncr.22958 · DOI
- 10.1111/j.1349-7006.2008.00866.x · doi:10.1111/j.1349-7006.2008.00866.x
- Chiari R, 2000, Identification of a tumor‐specific shared antigen derived from an Eph receptor and presented to CD4 T cells on HLA class II molecules, Cancer Res, 60, 4855
- 10.1016/j.ccr.2009.04.009 · DOI · Paper page
- 10.1038/sj.onc.1210957 · DOI
- 10.1158/0008-5472.CAN-08-1845 · DOI · Paper page
- 10.1038/nn.2231 · DOI · Paper page
- 10.1242/jcs.036467 · DOI · Paper page
- 10.1083/jcb.200306033 · DOI · Paper page
- 10.1242/jcs.02842 · DOI · Paper page
- 10.1002/dvdy.20978 · DOI · Paper page
- Pan M, 2005, Overexpression of EphA2 gene in invasive human breast cancer and its association with hormone receptor status [ASCO Annual Meeting Proceedings], J Clin Oncol, 23, 9583, 10.1200/jco.2005.23.16_suppl.9583 · doi:10.1200/jco.2005.23.16_suppl.9583
- 10.1007/BF02893405 · DOI
- Maru Y, 1990, Overexpression confers an oncogenic potential upon the eph gene, Oncogene, 5, 445
- 10.1111/j.1349-7006.2004.tb03194.x · doi:10.1111/j.1349-7006.2004.tb03194.x
- 10.1016/j.bbrc.2006.02.099 · DOI
200 of 206 shown
Cited by
The Achilles' heel of senescent cells: from transcriptome to senolytic drugs
Zhu, Y., Tchkonia, T., Pirtskhalava, T., Gower, A. C., Ding, H., Giorgadze, N., Palmer, A. K., Ikeno, Y., Hubbard, G. B., Lenburg, M., et al. (2015) · Aging Cell · doi:10.1111/acel.12344 · Cited by 2,584
“Together with ephrin ligands, these receptors coordinate tissue and organ patterning, cell positioning, and cell survival during development and tissue turnover in a cell type-specific manner (Xi et al., 2012).”
BackgroundInfluentialState-of-the-Art Strategies for Targeting RET-Dependent Cancers
Subbiah, V., Yang, D., Velcheti, V., Drilon, A., & Meric-Bernstam, F. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02551 · Cited by 258
Promiscuous and specific recognition among ephrins and Eph receptors
Dai, D., Huang, Q., Nussinov, R., & Ma, B. (2014) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2014.07.002 · Cited by 51
Druggable Orthosteric and Allosteric Hot Spots to Target Protein-protein Interactions
Ma, B., & Nussinov, R. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990073 · Cited by 45
Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine
Quinn, B. A., Wang, S., Barile, E., Das, S. K., Emdad, L., Sarkar, D., De, S. K., Morvaridi, S. K., Stebbins, J. L., Pandol, S. J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7931 · Cited by 39
Metadata
- Authors
- Xi, H., Wu, X., Wei, B., & Chen, L.
- Venue
- Journal of Cellular and Molecular Medicine
- Publisher
- Wiley
- Published
- 2012-12
- Volume
- 16
- Issue
- 12
- Pages
- 2894-2909
- ISSN
- 1582-1838 (ISSN-L)
- 1582-4934
- OpenAlex
- W2067487060
- Cited by
- 131
- References
- 2
- FWCI
- 3.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Eph receptors and ephrins as targets for cancer therapy. https://app.cochat.ai/papers/10.1111/j.1582-4934.2012.01612.x
- The paper
- Xi, H., Wu, X., Wei, B., & Chen, L. (2012). Eph receptors and ephrins as targets for cancer therapy. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/j.1582-4934.2012.01612.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.